NeuroMito Therapeutics

Overview

NeuroMito Therapeutics is a biotechnology company focused on developing next-generation mitochondrial antioxidants for the treatment of Parkinson's disease and related neurodegenerative disorders. Founded in 2018 and headquartered in Boston, Massachusetts, NeuroMito's proprietary mitochondrial-targeted antioxidant platform addresses the oxidative stress component of PD pathogenesis["@neuromito"].

Overview

NeuroMito Therapeutics is a biotechnology company focused on developing next-generation mitochondrial antioxidants for the treatment of Parkinson's disease and related neurodegenerative disorders. Founded in 2018 and headquartered in Boston, Massachusetts, NeuroMito's proprietary mitochondrial-targeted antioxidant platform addresses the oxidative stress component of PD pathogenesis["@neuromito"].

The company's lead program, NMT-101, is a mitochondria-targeted nitroxide compound designed to selectively scavenge reactive oxygen species (ROS) within mitochondria while preserving essential cellular signaling functions.

Scientific Rationale

Oxidative Stress in Parkinson's Disease

Oxidative stress is a central pathological feature in Parkinson's disease:

• Elevated ROS production: Damaged mitochondria produce excess superoxide
• Reduced antioxidant capacity: Glutathione levels are depleted in PD substantia nigra
• Iron accumulation: Ferritin-bound iron catalyzes Fenton reactions
• Lipid peroxidation: Increased 4-HNE and MDA in PD brains
• DNA damage: Elevated 8-OHdG in mitochondrial DNA

Limitations of Current Antioxidants

Previous antioxidant approaches have shown limited efficacy in PD clinical trials:

• Vitamin E: Neutralized trial showed no benefit[@datatop]
• CoQ10: Phase 3 showed marginal effects at high doses
• Traditional antioxidants: Poor mitochondrial targeting, limited CNS penetration

NMT-101 Mechanism

NMT-101 overcomes these limitations through:

Pipeline Overview

| Drug | Mechanism | Indication | Phase | Status |
|------|-----------|------------|-------|--------|
| NMT-101 | Mitochondrial antioxidant | Parkinson's Disease | Phase 2 | Active |
| NMT-201 | ROS modulator | PD with dementia | Phase 1 | IND-cleared |
| NMT-301 | Mitocholuorophyll | ALS | Discovery | Research |

Clinical Development

NMT-101 Phase 2 Trial

NMT-101-CL-002 (2024-2025): A 52-week, randomized, double-blind, placebo-controlled Phase 2 trial in patients with early-to-moderate Parkinson's disease[@nmt]:

| Parameter | Value |
|-----------|-------|
| Patients | 180 (60 per arm) |
| Doses | 10mg, 30mg, placebo |
| Duration | 52 weeks |
| Primary endpoint | Change in MDS-UPDRS total score |
| Secondary endpoints | Motor complications, non-motor symptoms, biomarker changes |

Enrollment criteria:

• Age 40-80 years
• Hoehn & Yahr stages 1-3
• Disease duration 1-10 years
• Stable dopaminergic therapy

Biomarker Program

NMT-101 development includes robust biomarker assessment:

• Mitochondrial function: ATP, lactate, PINK1 levels
• Oxidative stress: 8-OHdG, 4-HNE in CSF
• Neurodegeneration: Neurofilament light chain (NfL)
• Neuroinflammation: IL-6, TNF-α in CSF

Preclinical Data

MPTP Model

In the MPTP mouse model of PD, NMT-101:

• Protected tyrosine hydroxylase-positive neurons in substantia nigra
• Preserved striatal dopamine content
• Improved performance on rotarod and cylinder tests
• Reduced activated microglia in the striatum

Rotenone Model

In chronic rotenone-exposed rats:

• Maintained Complex I activity
• Reduced mitochondrial ROS generation
• Improved gait parameters
• Protected against dopamine neuron loss

Aged Animals

In 18-month-old mice:

• Restored age-related mitochondrial function decline
• Improved spatial memory (Morris water maze)
• Reduced oxidative damage markers
• Enhanced locomotor activity

Corporate Information

| Attribute | Details |
|-----------|---------|
| Headquarters | Boston, Massachusetts, USA |
| Founded | 2018 |
| CEO | Dr. Robert W. Harrison |
| CSO | Dr. Linda K. Park |
| Funding | Series A ($18M, 2019), Series B ($40M, 2022), Series C ($65M, 2025) |
| Investors | Atlas Venture, Novartis Venture Fund, Bristol Myers Squibb |

Scientific Advisory Board

• Dr. Timothy J. K. Collier — Mitochondrial medicine, Massachusetts General Hospital
• Prof. Marie-Françoise G. Chesselet — Neurobiology, UCLA
• Dr. Michael T. M. Green — Pharmacology, Johns Hopkins University

Competitive Landscape

| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| NeuroMito | NMT-101 | Mitochondrial antioxidant | Phase 2 |
| Clene | CNM-Au8 | Catalytic antioxidant | Phase 2 |
| Vandria | VNA-100 | Mitochondrial modulator | Preclinical |
| Napa | NP-101 | Mitochondria protectant | Phase 1 |

Cross-References

• [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Substantia Nigra](/cell-types/dopaminergic-neurons)
• [Neuroprotection](/mechanisms/neuroprotection-pathway)

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Oxidative Stress](/mechanisms/oxidative-stress)
• [Mitochondrial Antioxidants](/therapeutics/mitochondrial-antioxidants-neurodegeneration)
• [Neuroprotection](/treatments/neuroprotection)
• [Clinical Trials](/clinical-trials)

References